Business Wire

PA-BOOMI

8.5.2024 18:01:35 CEST | Business Wire | Press release

Share
Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024

Boomi™, the intelligent integration and automation leader, today unveiled its vision for the company’s future, along with strategic acquisitions and key product announcements at Boomi World 2024. With more than 20,000 global customers and a network of approximately 800 partners worldwide, Boomi is leading the industry towards the future with a focus on integration and automation, API management, and data management, all made more important and powerful than ever with the emergence of the AI economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508488304/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024 (Graphic: Business Wire)

In his keynote, Boomi CEO Steve Lucas emphasized the transformative impact of integration platform as a service (iPaaS), spotlighting its pivotal role in enhancing speed, agility, and effectiveness across business operations. Lucas explained how Boomi’s iPaaS streamlines connectivity — seamlessly linking people, systems, devices, and applications — for building stronger relationships and enabling swift, informed decision-making through real-time data access.

But Boomi recognizes the opportunity to take connectivity even further, and to bring connectivity solutions to more companies in more areas of business and IT.

“Connectivity,” Lucas pointed out, “remains a critical challenge for almost every organization. The chief culprit is digital fragmentation, a byproduct of digital shifts that, paradoxically, lead to digital silos and disjointed technical architectures that leave the average enterprise now juggling over 364 applications and numerous API gateways.”

The emergence of the AI economy has further highlighted the challenges of digital fragmentation. "AI thrives on reliable, secure, and current data, yet too often, this data is fragmented, difficult to govern, and not securely managed," Lucas noted. “What companies urgently need is a unified, enterprise-scale platform that not only bridges APIs, applications, data, and AI models, but also accelerates digital transformation.”

To address these pressing challenges, Boomi unveiled key announcements at Boomi World, including:

New Boomi Enterprise Platform Vision

Boomi has expanded and deepened the capabilities of the Boomi Enterprise Platform with:

  • Next-generation API management for the AI economy
  • An AI agent framework that provides out-of-the-box AI agents, pluggability for 3rd party AI agents, as well as the ability to automate AI orchestration workflows
  • Enhanced data management to support data quality, data lineage, and metadata management

Next-Generation API Management for the AI Economy

Joining Lucas onstage, Matt McLarty, CTO at Boomi, explained that “companies today suffer from API sprawl: API gateways are everywhere, and there’s no effective global view or management dashboard for discovering, governing, and securing them, let alone rationalizing API investments and promoting best-in-class APIs for adoption. The AI economy requires next-generation API management (APIM) that accounts for a fragmented APIM landscape and can handle the demands of enterprise-grade scalability and security that AI workloads place on APIM solutions.”

To solve this problem, Boomi announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group. Both acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end enterprise platform.

Boomi AI Agent Framework

To accelerate innovation in the AI economy, Boomi introduced the Boomi AI agent framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.

Boomi introduced four new agents built into the platform that make use of the new AI agent framework, including:

  • Boomi Answers: Agent for providing prescriptive help
  • Boomi DataDetective: Agent for classifying data fields, protecting sensitive data like personally identifiable information (PII), and tracking where data is being moved
  • Boomi DesignGen: Agent for autonomously building integrations
  • Boomi Scribe: Agent for automatically documenting existing and built-by-AI integrations

In addition, the Boomi AI agent framework is open to third parties, and supports pluggable AI agents, allowing customers to integrate third-party AI agents into the platform via APIs or Boomi GPT.

In his Boomi World keynote, Lucas announced a strategic OEM agreement with Vianai Systems, a leading provider of conversational AI solutions for finance, and demonstrated one of the first third-party AI agents, Boomi FinTalk powered by Vianai. Customers can seamlessly connect to Boomi FinTalk powered by Vianai via Boomi GPT, leveraging Boomi’s AI agent framework. Using Boomi, the agent connects to sources of financial data in ERP systems, databases, documents, customers’ data lakes, and other data, and enables users to ask questions of their data through a natural language interface to discover and analyze financial data and trends in real-time, for immediate actionable insights.

“Technology and business leaders have struggled to leverage the power of generative AI in their enterprises due to the very real issues of accuracy and security, relevance to business users with domain-specific requirements, and the inability to query both structured and unstructured data and systems in natural language,” said Dr. Vishal Sikka, Founder and CEO, Vianai Systems. “With Boomi FinTalk powered by Vianai, we are solving these issues with Boomi’s vast integration capabilities and Vianai’s conversational AI application for CFOs and finance users, enabling real-time, accurate, and actionable insights to drive business transformation.”

Trusted Data Management

Boomi also announced Boomi DataHub, a trusted data foundation for operational, analytical, and AI workloads. A high velocity, high quality data access layer, Boomi DataHub provides master data management, integration pipelines, and a framework that will expand over time to provide other data management capabilities, including enterprise scale movement and standardization of data for AI and analytics initiatives.

“Centralizing data has proved to be a dead end for companies,” said Lucas. “A better approach is to build connectivity, governance, and automation into the IT resources companies already have, taking advantage of AI to make this work faster and easier than ever before. With the Boomi Enterprise Platform, we’re giving customers the foundation they need for connecting and managing all their data, and for accelerating AI and API development. Using Boomi, customers can say goodbye to the digital fragmentation that’s been undermining their digital transformation efforts, and finally get the comprehensive visibility, control, and automation they need.”

Check out all the latest announcements from Boomi World 2024 here.

Additional Resources

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508488304/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye